carubicin has been researched along with Soft-Tissue-Neoplasms* in 7 studies
4 trial(s) available for carubicin and Soft-Tissue-Neoplasms
Article | Year |
---|---|
[Experience with using carminomycin in oncological clinical practice].
Carminomycin is an original antitumor antibiotic from the anthracycline group isolated at the Institute of New Antibiotics (USSR) in 1973. Pharmacological investigation of carminomycin revealed its satisfactory absorption from the gastrointestinal tract which proved to be a distinguishing property of the antibiotic as compared to other anthracyclines such as adriamycin and rubomycin. The clinical trials of carminomycin showed that it was mainly active against soft tissue sarcoma and breast cancer, lymphosarcoma, neuroblastoma, Wilms' tumor and Ewing's sarcoma in children, as well as acute leukemia. Various regimens for the antibiotic administration were applied: short-term, single and long-term. Suppression of hemopoiesis was considered as a limiting toxic effect. By the data available carminomycin had lower cardiotoxicity as compared with rubomycin and adriamycin. Development of oral carminomycin is believed promising. Topics: Adult; Breast Neoplasms; Carubicin; Child; Female; Humans; Kidney Neoplasms; Leukemia, Myeloid, Acute; Liver Neoplasms; Neoplasms; Sarcoma; Soft Tissue Neoplasms; Uterine Neoplasms; Wilms Tumor | 1992 |
[Results of chemotherapy of soft tissue sarcoma in adults].
Topics: Adult; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Carubicin; Clinical Trials as Topic; Cyclophosphamide; Dacarbazine; Dactinomycin; Doxorubicin; Humans; Lymphatic Metastasis; Neoplasm Metastasis; Random Allocation; Sarcoma; Soft Tissue Neoplasms; Vincristine | 1984 |
Phase I clinical study of carminomycin: its activity against soft tissue sarcomas.
Topics: Antibiotics, Antineoplastic; Carubicin; Clinical Trials as Topic; Drug Evaluation; Humans; Leukopenia; Sarcoma; Soft Tissue Neoplasms | 1977 |
[Therapeutic use of carminomycin in soft tissue sarcomas].
A total of 39 patients with sarcoma of the soft tissues were treated with carminomycin administered intravenously in doses of 10-15 mg twice a week, the total dose being 60-70 mg. The intervals between the courses were 1 month. The objective effect was observed in 17 out of 39 patients, i. e. 43.6%. The tumor decrease was registered in 6 out of 15 patients with leuomyosarcoma, in 3 out of 6 patients with synovial sarcoma, in 2 out of 4 patients with robdomyosarcoma, in 1 out of 4 patients with angiosarcoma, in 1 out of 3 patients with fibrosarcoma, in 1 patient with liposarcoma and in 3 out of 5 patients with stromal sarcoma of the uterus. A necessity for repeated treatment courses in spite of a positive effect or absence of the disease progress is underlined. Topics: Aged; Antibiotics, Antineoplastic; Carubicin; Clinical Trials as Topic; Drug Evaluation; Drug Therapy, Combination; Female; Humans; Male; Middle Aged; Moscow; Neoplasm Metastasis; Remission, Spontaneous; Sarcoma; Soft Tissue Neoplasms | 1976 |
3 other study(ies) available for carubicin and Soft-Tissue-Neoplasms
Article | Year |
---|---|
Plasma concentrations of carminomycin and carminomycinol in man, measured by high pressure liquid chromatography.
In 9 patients with advanced malignant disease who received carminomycin (CMM) in an i.v. bolus injection (dose 18 mg/m2), curves of plasma concentrations of CMM and carminomycinol (CMMOH), a metabolite, versus time were constructed. For determination of plasma concentrations, high pressure liquid chromatography was used. For CMM and CMMOH the median areas under the curves (AUC's) were 31 (range 4-57) X 10(-8) mol/Ql/hr (measured over 24 hr) and 100 (range 309-158) X 10(-8) mol/l/hr (measured over 48 hr) respectively. From the data an accumulation of CMMOH in patients receiving treatments separated by brief intervals ban be predicted (half-life time of plasma disappearance for CMMOH was 2 days). Clinical toxicity was lowest in those 3 patients showing the lowest AUC for both CMM and CMMOH. Topics: Breast Neoplasms; Carubicin; Chromatography, High Pressure Liquid; Daunorubicin; Humans; Sarcoma; Soft Tissue Neoplasms; Time Factors | 1982 |
Modern problems of clinical chemotherapy of malignant tumours.
The paper reports on a trial in which nitrosomethylurea (NMU) was compared with CCNU both in combination with vincristine and dactinomycin or the same combination with DTIC in the treatment of disseminated skin melanoma. The long-term results were statistically better in the groups with NMU than in that with CCNU while there was no statistical difference regarding the complete regression. A second trial compared NMU with CCNU in the treatment of small cell carcinoma in a regimen of combined chemo-radiotherapy. No statistical difference was to be noticed in regard to objective response and median live duration. In comparison with regimens including adriamycin the study showed an equal effectiveness of the two drugs. A third part deals with carminomycin therapy in metastatic soft tissue sarcomas and with the preventive role of postoperative 5-fluorouracil in gastric carcinoma and colo-rectal cancer. Topics: Antineoplastic Agents; Carcinoma, Small Cell; Carubicin; Dacarbazine; Dactinomycin; Drug Therapy, Combination; Female; Humans; Lomustine; Lung Neoplasms; Male; Melanoma; Methylnitrosourea; Neoplasms; Sarcoma; Skin Neoplasms; Soft Tissue Neoplasms; Vincristine | 1980 |
[Carminomycin in drug combination in breast cancer and soft tissue sarcomas].
Thirteen patients with neglected mammary cancer were treated with karminomycin in combination with hexamethylmelamine. Twelve out of the 13 patients were previously subjected many times to cytostatic and hormonal therapy. A significant therapeutic effect was registered in 5 out the 13 patients (38 per cent), the total rate of the objective effect being 54 per cent. The remission period with a significant effect was 6 to 9 months. Fifteen patients with sarcoma metastases in the soft tissue were treated with karminomycin in combnation with methotrexate and cyclophosphane. A significant therapeutic effect was observed in 45 per cent of the cases with synovial sarcoma, hemangyopericitoma and leuomyosarcoma, the remission period being 4 to 12 months. The side effects of the above combinations were determined. Topics: Aged; Altretamine; Antibiotics, Antineoplastic; Breast Neoplasms; Carubicin; Cyclophosphamide; Drug Therapy, Combination; Female; Humans; Lymphatic Metastasis; Methotrexate; Middle Aged; Neoplasm Metastasis; Sarcoma; Soft Tissue Neoplasms | 1977 |